[go: up one dir, main page]

MX2008011074A - Metodo anticonceptivo oral multifasico de ciclo prolongado. - Google Patents

Metodo anticonceptivo oral multifasico de ciclo prolongado.

Info

Publication number
MX2008011074A
MX2008011074A MX2008011074A MX2008011074A MX2008011074A MX 2008011074 A MX2008011074 A MX 2008011074A MX 2008011074 A MX2008011074 A MX 2008011074A MX 2008011074 A MX2008011074 A MX 2008011074A MX 2008011074 A MX2008011074 A MX 2008011074A
Authority
MX
Mexico
Prior art keywords
estrogen
ethinyl estradiol
amount equivalent
phase
equivalent
Prior art date
Application number
MX2008011074A
Other languages
English (en)
Inventor
Herman Ellman
Original Assignee
Warner Chilcott Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Chilcott Co Inc filed Critical Warner Chilcott Co Inc
Publication of MX2008011074A publication Critical patent/MX2008011074A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La invención proporciona un método multifásico de anticoncepción que comprende las etapas de: administrar consecutivamente a una mujer en edad fértil una composición de la fase 1 que contiene un progestógeno en una cantidad equivalente a aproximadamente 0.3 hasta aproximadamente 1.5 mcg de acetato de noretindrona y un estrógeno en una cantidad equivalente a aproximadamente 5 hasta aproximadamente 15 mcg de etnil estradiol durante aproximadamente 7 hasta aproximadamente 14 días; una composición de la fase III que contiene un progestógeno en una cantidad equivalente a aproximadamente 0.3 hasta aproximadamente 1.5 mcg del acetato de noretindrona un estrógeno en una cantidad equivalente a aproximadamente 10 hasta aproximadamente 25 mcg de etinil estradiol durante aproximadamente 14 hasta aproximadamente 22 días; una composición de la fase III que contiene un progestógeno en una cantidad equivalente a aproximadamente 0.3 hasta aproximadamente 1.5 mcg de acetato de noretindrona y un estrógeno en una cantidad equivalente a aproximadamente 15 hasta aproximadamente 35 mcg de etinil estradiol durante aproximadamente 20 hasta aproximadamente 31 días; y una composición de la fase IV opcional que contiene (i) un estrógeno en una cantidad equivalente a aproximadamente 5 hasta aproximadamente 20 mcg del etinil estradiol, o (ii) un placebo o un componente no esteroidal, o (iii) una combinación de (i) y (ii), durante aproximadamente 2 hasta aproximadamente 8 días. La cantidad equivalente de etinil estradiol del estrógeno en cada una de las fases II y III sucesivas es de al menos 5 mcg mayor que la cantidad equivalente del etinil estradiol del estrógeno en la fase inmediatamente precedente.
MX2008011074A 2006-03-02 2007-02-09 Metodo anticonceptivo oral multifasico de ciclo prolongado. MX2008011074A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77806706P 2006-03-02 2006-03-02
US79265306P 2006-04-18 2006-04-18
PCT/US2007/003508 WO2007106264A2 (en) 2006-03-02 2007-02-09 Extended cycle multiphasic oral contraceptive method

Publications (1)

Publication Number Publication Date
MX2008011074A true MX2008011074A (es) 2008-09-10

Family

ID=38229300

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008011074A MX2008011074A (es) 2006-03-02 2007-02-09 Metodo anticonceptivo oral multifasico de ciclo prolongado.

Country Status (8)

Country Link
US (1) US8063030B2 (es)
EP (1) EP1993531B1 (es)
CA (1) CA2640520C (es)
ES (1) ES2558030T3 (es)
IL (1) IL193013A (es)
MX (1) MX2008011074A (es)
SG (1) SG172654A1 (es)
WO (1) WO2007106264A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007511533A (ja) * 2003-11-14 2007-05-10 ワーナー・チルコット・カンパニー・インコーポレーテッド 段階的エストロゲン避妊薬
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2013090117A1 (en) 2011-12-13 2013-06-20 Arstat, Inc. A multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
JP6863547B2 (ja) 2015-06-18 2021-04-21 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロール成分を含有する口腔内崩壊性投与単位
MA44206B1 (fr) 2015-06-18 2021-04-30 Estetra Sprl Comprimé orodispersible comprenant estetrol
JP6866560B2 (ja) 2015-06-18 2021-04-28 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロール成分を含有する口腔内崩壊性投与単位
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35724E (en) * 1982-04-28 1998-02-03 Bio-Technology General Corp. Contraception system and method
US5010070A (en) * 1987-06-15 1991-04-23 Warner-Lambert Company Graduated estrogen contraceptive
US4962098A (en) * 1987-06-15 1990-10-09 Warner-Lambert Company Graduated estrogen contraceptive
DE4313926A1 (de) * 1993-04-28 1994-11-03 Jenapharm Gmbh Pharmazeutisches Mehrphasenpräparat zur hormonalen Kontrazeption
DE4411585A1 (de) * 1994-03-30 1995-10-05 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19525017A1 (de) 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
DE19531936A1 (de) 1995-08-17 1997-02-20 Schering Ag Kombinationspräparat zur Kontrazeption, Kits diese enthaltend und eine Methode diese verwendend
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
DE69731092T2 (de) * 1996-07-26 2005-02-10 Wyeth Orales contrazeptivum
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US6251956B1 (en) 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
DE19739916C2 (de) 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
WO2002094280A1 (en) 2001-05-23 2002-11-28 Pantarhei Bioscience B.V. Means and method for hormonal contraception
NZ533242A (en) 2001-12-05 2007-11-30 Duramed Pharmaceuticals Inc Oral extended regime contraceptive package
US20040142914A1 (en) 2002-03-11 2004-07-22 Friedman Andrew Joseph Extended transdermal contraceptive regimens
US20030219471A1 (en) 2002-03-11 2003-11-27 Caubel Patrick Michel Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens
JP2005519962A (ja) 2002-03-11 2005-07-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルファターゼを阻害する継続的プロゲストゲン避妊レジメン
US7772219B2 (en) 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US7855190B2 (en) 2003-07-16 2010-12-21 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
BRPI0414945A (pt) 2003-10-01 2006-11-07 Janssen Pharmaceutica Nv regimes contraceptivos trifásicos estendidos
JP2007511533A (ja) * 2003-11-14 2007-05-10 ワーナー・チルコット・カンパニー・インコーポレーテッド 段階的エストロゲン避妊薬
US20050113350A1 (en) 2003-11-26 2005-05-26 Bernd Duesterberg Extended use combination comprising estrogens and progestins
US7569560B2 (en) * 2004-03-19 2009-08-04 Warner Chilcott Company Llc Extended cycle multiphasic oral contraceptive method
DE102004019743B4 (de) * 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
BRPI0510024A (pt) * 2004-05-14 2007-09-25 Irm Llc compostos e composições como modulares de ppar
WO2007002910A1 (en) * 2005-06-29 2007-01-04 Warner Chilcott Company, Inc. Quadraphasic continuous graduated estrogen contraceptive

Also Published As

Publication number Publication date
IL193013A0 (en) 2009-08-03
CA2640520C (en) 2014-04-22
WO2007106264A3 (en) 2008-05-02
WO2007106264A2 (en) 2007-09-20
CA2640520A1 (en) 2007-09-20
SG172654A1 (en) 2011-07-28
US8063030B2 (en) 2011-11-22
IL193013A (en) 2011-11-30
US20070207945A1 (en) 2007-09-06
ES2558030T3 (es) 2016-02-01
EP1993531A2 (en) 2008-11-26
EP1993531B1 (en) 2015-10-14

Similar Documents

Publication Publication Date Title
MX2008011074A (es) Metodo anticonceptivo oral multifasico de ciclo prolongado.
CA2542854A1 (en) Graduated estrogen contraceptive
CA2609336C (en) Quadraphasic continuous graduated estrogen contraceptive
RU2009120528A (ru) Способы гормональной терапии возрастающими дозами в режиме пролонгированного цикла
TR200101826T2 (tr) Üç-fazlı ağızdan alınan gebelik önleyici ilaç
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
JP2007535519A5 (es)
JP2008540482A5 (es)
JP2009512658A5 (es)
AR049112A1 (es) Composiciones, metodos y kit, para el tratamiento de trastorno disforico premenstrual
MX2007013137A (es) Regimen anticonceptivo con dosificacion de estrogeno ampliada.
WO2006042021B1 (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
WO2005092441A3 (en) Extended cycle multiphasic oral contraceptive method
ATE278406T1 (de) Orales contrazeptivum
AR049197A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona
NO20072893L (no) Fast, peroralt prevensjonsmiddel
HRP20100513T1 (hr) Višefazni kontracepcijski pripravak zasnovan na prirodnom estrogenu
NO20072687L (no) Farmasoytisk prevensjonspreparat
TW200638951A (en) Solid oral pharmaceutical form for contraception
ME01056B (me) Upotreba estradiolvalerata i dienogesta za oralno liječenje disfunkcionalnog uterinog krvarenja u kontracepcijskom metodu
WO2008017331A3 (de) Perorale arzneiform mit dienogest und ethinylestradiol zur kontrazeption
WO2007042111A3 (de) Verwendung von estradiolvalerat in kombination mit dienogest zur oralen therapie der dysf unktionellen uterinen blutung in einheit mit einer oralen kontrazeption
HRP20200155T1 (hr) Farmaceutski pripravak koji obuhvaća drospirenon i kontracepcijski komplet
MXPA06004547A (es) Anticonceptivo estrogenico graduado

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration